Cancer Treatment by Electromagnetic Fields Goes Mainstream
Before and after applying 200khz frequencies to brain cancer. Disease has stabilized.
- Eilon D. Kirson *, Vladimír Dbalý † , František Tovaryš † , Josef Vymazal † , Jean F. Soustiel ‡ , Aviran Itzhaki *, Daniel Mordechovich *, Shirley Steinberg-Shapira *, Zoya Gurvich *, Rosa Schneiderman *, Yoram Wasserman *, Marc Salzberg § , Bernhard Ryffel ¶ , Dorit Goldsher ‡ , Erez Dekel ‖ , and Yoram Palti * , ** , ††
- *NovoCure Limited, Matam Advanced Technology Centre, Haifa 31905, Israel;
- †Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic;
- ‡Rambam Medical Center, PO Box 9602, Haifa 31096, Israel;
- §Basel University Hospitals, Hebelstrasse 32, 4031 Basel, Switzerland;
- ¶Centre National de la Recherche Scientifique, Laboratoire d’immunologie et Embryologie Moléculaire, Rue de la Ferollerie, 45071 Orleans, France;
- ‖Weizmann Institute of Science, PO Box 26, Rehovot 76100, Israel; and
- **B. Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Technion City, Haifa 32000, Israel
- Communicated by Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, April 5, 2007 (received for review January 15, 2007)
We have recently shown that low intensity, intermediate frequency, electric fields inhibit by an anti-microtubule mechanism of action, cancerous cell growth in vitro. Using implanted electrodes, these fields were also shown to inhibit the growth of dermal tumors in mice. The present study extends these findings to additional cell lines [human breast carcinoma; MDA-MB-231, and human non-small-cell lung carcinoma (H1299)] and to animal tumor models (intradermal B16F1 melanoma and intracranial F-98 glioma) using external insulated electrodes. These findings led to the initiation of a pilot clinical trial of the effects of TTFields in 10 patients with recurrent glioblastoma (GBM). Median time to disease progression in these patients was 26.1 weeks and median overall survival was 62.2 weeks. These time to disease progression and OS values are more than double the reported medians of historical control patients. No device-related serious adverse events were seen after >70 months of cumulative treatment in all of the patients. The only device-related side effect seen was a mild to moderate contact dermatitis beneath the field delivering electrodes. We conclude that TTFields are a safe and effective new treatment modality which effectively slows down tumor growth in vitro, in vivo and, as demonstrated here, in human cancer patients.
Despite using frequencies that are not optimal for eliminating cancer cells and not using frequencies to eliminate Rife BX BY and Gregory cancer virus infections, significant benefit was found with long term treatment of brain cancer with an electromagnetic device designed by NovoCure. A clinical trial is well under way.